Dr Tarek Mamdouh Abdelghany
Shireen Hedya
Carol De Santis
Dr Jason Gill
Professor Matt Wright
et al. | Potential for cardiac toxicity with methylimidazolium ionic liquids | 2023 |
|
Dr Rachael Redgrave
Dr Emily Dookun
Laura Booth
Dr Maria Camacho Encina
Dr Omowumi Folaranmi
et al. | Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction | 2023 |
|
Dr Rachael Redgrave
Dr Maria Camacho Encina
Dr Simon Tual-Chalot
Dr Omowumi Folaranmi
Dr Carmen Martin-Ruiz
et al. | The senescence-associated secretory phenotype as a biomarker for age-related myocardial remodelling and cardiovascular disease | 2023 |
|
Dr Simon Findlay
Dr Jason Gill
| Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review | 2022 |
|
Dr Alistair Brown
Alaa Aljohani
Fatimah Alsalem
Dr Jason Gill
Dr Jon Sellars
et al. | Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach | 2020 |
|
Dr Simon Findlay
Dr Jason Gill
Professor Ruth Plummer
Carol De Santis
Dr Chris Plummer
et al. | Chronic cardiovascular toxicity in the older oncology patient population | 2019 |
|
Dr Jason Gill
| Collaboration, Competition and Publication in Toxicology: views of British Toxicology Society Members | 2019 |
|
Dr Rachel Oldershaw
Dr Andrew Owens
Rachel Telfer-Sutherland
Martin Linney
Rachel Liddle
et al. | Human Cardiac-Mesenchymal Stem Cell-Like Cells, a Novel Cell Population with Therapeutic Potential | 2019 |
|
Dr Alistair Brown
Ahmed Aljohani
Dr Jason Gill
Dr Jon Sellars
| Identification of novel benzoxa-[2,1,3]-diazole substituted amino acid hydrazides as potential anti-tubercular agents | 2019 |
|
Dr Jason Gill
| Trichostatin A blocks aldosterone-induced Na+ Transport and control of serum- and gulcocorticoid-inducible kinase 1 in cortical collecting duct cells | 2019 |
|
Dr Jason Gill
Kimberly Rockley
Carol De Santis
Asma Mohamed
| Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics | 2019 |
|
Professor Adam Todd
Dr Jason Gill
| Anticancer Therapeutics: From Drug Discovery to Clinical Applications | 2018 |
|
Dr Jason Gill
| Aldosterone-induced Na+ Absorption is Regulated by Protein Acetylation in a Cellular Model of the Cortical Collecting Duct | 2017 |
|
Kimberly Rockley
Dr Jason Gill
| Characterisation of Novel Molecular Mechanisms Involved in Anthracycline-Induced Cardiotoxicity | 2017 |
|
Dr Jonathan Harburn
Dr Jason Gill
| Rationalized Computer-Aided design of Matrix Metalloprotease-Selective Prodrugs | 2017 |
|
Dr Jason Gill
| Anticancer RuII and RhIII Piano-Stool Complexes that are Histone Deacetylase Inhibitors | 2016 |
|
Kimberly Rockley
Professor Gavin Richardson
Dr Jason Gill
| Characterisation of novel molecular mechanisms involved in anthracycline-induced cardiotoxicity | 2016 |
|
Hannah Bows
Dr Jason Gill
| Integration of pharmacogenetic principles as a core thread in the undergraduate pharmacy curriculum | 2016 |
|
Dr Jason Gill
| Oncology Activity | 2016 |
|
Dr Jason Gill
Kimberly Rockley
| Pyridylphosphinate Metal Complexes: Synthesis, Structural Characterisation and Biological Activity | 2016 |
|
Dr Jason Gill
| Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy | 2014 |
|
Dr Jason Gill
| MT-MMP cleavage profiling using rapid endopeptidase profiling library (REPLi) | 2014 |
|
Dr Jason Gill
| The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity | 2014 |
|
Dr Jason Gill
| Antitumour activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder | 2013 |
|
Dr Anja Krippner-Heidenreich
Dr Jason Gill
| Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity | 2008 |
|
